CoChat

Selective RAF inhibitor impairs ERK 1/2 phosphorylation and growth in mutant NRAS, vemurafenib‐resistant melanoma cells

Open access
Le, Kaitlyn, Blomain, Erik S., Rodeck, Ulrich, Aplin, Andrew E. · 2013 · Pigment Cell & Melanoma Research
Cited by 70

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Summary: The RAF inhibitor vemurafenib achieves remarkable clinical responses in mutant BRAF melanoma patients. However, vemurafenib is burdened by acquired drug resistance and by the side effects associated with its paradoxical activation of the ERK 1/2 pathway in wild‐type BRAF cells. This paradoxical effect has driven the development of a new class of RAF inhibitors. Here, we tested one of these selective, non‐paradox‐inducing RAF inhibitors termed paradox‐breaker‐04 (PB 04) or PLX 7904. Consistent with its design, PB 04 is able to efficiently inhibit activation of ERK 1/2 in mutant BRAF melanoma cells but does not hyperactivate ERK 1/2 in mutant RAS‐expressing cells. Importantly, PB 04 inhibited ERK 1/2 phosphorylation in mutant BRAF melanoma cells with acquired resistance to vemurafenib/PLX 4720 that is mediated by a secondary mutation in NRAS. Consistent with ERK 1/2 reactivation driving the re‐acquisition of malignant properties, PB 04 promoted apoptosis and inhibited entry into S phase and anchorage‐independent growth in mutant N‐RAS‐mediated vemurafenib‐resistant cells. These data indicate that paradox‐breaker RAF inhibitors may be clinically effective as a second‐line option in a cohort of acquired vemurafenib‐resistant patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/pcmr.12092

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

Metadata

Authors
Le, K., Blomain, E. S., Rodeck, U., & Aplin, A. E.
Venue
Pigment Cell & Melanoma Research
Publisher
Wiley
Published
2013-04-08
Volume
26
Issue
4
Pages
509-517
ISSN
  • 1755-1471 (ISSN-L)
  • 1755-148X
OpenAlex
W2070819820
Cited by
70
References
5
FWCI
5.78
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.